EGFR and non-small cell lung carcinoma: In another retrospective study assessing the optimal treatment strategy for EGFR-mutant NSCLC with BMs [45], EGFR-TKIs plus SRS significantly improved OS compared to EGFR-TKI without SRS for patients with Lung-mol graded prognostic assessment (GPA) ≥ 3 but not for those with Lung-mol GPA < 3.